back to cluster viewer
cluster path 100001111110
58 words, 7,753 tokens
freq alpha suffix
Words in frequency order
1 | achieving | 4,385
|
2 | reaching | 2,118
|
3 | approaching | 360
|
4 | losing | 314
|
5 | attaining | 312
|
6 | tolerating | 86
|
7 | regaining | 78
|
8 | declaring | 24
|
9 | nondeletional | 6
|
10 | recreating | 5
|
11 | 'setting | 3
|
12 | 2,351 | 3
|
13 | recalibrating | 3
|
14 | scorpiops | 3
|
15 | 61-years | 2
|
16 | apportioning | 2
|
17 | asai | 2
|
18 | chuanping | 2
|
19 | eating/feeling | 2
|
20 | ekbatan | 2
|
21 | ha-therapy | 2
|
22 | pre-9/11 | 2
|
23 | spermograms | 2
|
24 | 0.78mg/ml | 1
|
25 | 1-s-duration | 1
|
26 | 1020-hz | 1
|
27 | 11,925 | 1
|
28 | 14.in | 1
|
29 | 16654 | 1
|
30 | 2002-4 | 1
|
31 | 2003/2007 | 1
|
32 | btk-based | 1
|
33 | bupropion-hydrochloride | 1
|
34 | cardiology–suggested | 1
|
35 | celastrol-containing | 1
|
36 | chaerilus | 1
|
37 | common-law | 1
|
38 | consciousness≥1 | 1
|
39 | disease/diagnostic | 1
|
40 | england-adopted | 1
|
41 | fbih | 1
|
42 | guideline-derived | 1
|
43 | hyperaspidinols | 1
|
44 | lvdd-with | 1
|
45 | mice—and | 1
|
46 | newcastle-lake | 1
|
47 | non-p53 | 1
|
48 | pathogen-stimulated | 1
|
49 | pegaptanib-associated | 1
|
50 | perfectsil | 1
|
51 | pyrimidine-rich | 1
|
52 | rapid-turnaround | 1
|
53 | rca-d | 1
|
54 | re-reporting | 1
|
55 | resource-impact | 1
|
56 | rheumatics | 1
|
57 | technology.though | 1
|
58 | us/european | 1
|
Words in alphabetical order
1 | 'setting | 3
|
2 | 0.78mg/ml | 1
|
3 | 1-s-duration | 1
|
4 | 1020-hz | 1
|
5 | 11,925 | 1
|
6 | 14.in | 1
|
7 | 16654 | 1
|
8 | 2,351 | 3
|
9 | 2002-4 | 1
|
10 | 2003/2007 | 1
|
11 | 61-years | 2
|
12 | achieving | 4,385
|
13 | apportioning | 2
|
14 | approaching | 360
|
15 | asai | 2
|
16 | attaining | 312
|
17 | btk-based | 1
|
18 | bupropion-hydrochloride | 1
|
19 | cardiology–suggested | 1
|
20 | celastrol-containing | 1
|
21 | chaerilus | 1
|
22 | chuanping | 2
|
23 | common-law | 1
|
24 | consciousness≥1 | 1
|
25 | declaring | 24
|
26 | disease/diagnostic | 1
|
27 | eating/feeling | 2
|
28 | ekbatan | 2
|
29 | england-adopted | 1
|
30 | fbih | 1
|
31 | guideline-derived | 1
|
32 | ha-therapy | 2
|
33 | hyperaspidinols | 1
|
34 | losing | 314
|
35 | lvdd-with | 1
|
36 | mice—and | 1
|
37 | newcastle-lake | 1
|
38 | non-p53 | 1
|
39 | nondeletional | 6
|
40 | pathogen-stimulated | 1
|
41 | pegaptanib-associated | 1
|
42 | perfectsil | 1
|
43 | pre-9/11 | 2
|
44 | pyrimidine-rich | 1
|
45 | rapid-turnaround | 1
|
46 | rca-d | 1
|
47 | re-reporting | 1
|
48 | reaching | 2,118
|
49 | recalibrating | 3
|
50 | recreating | 5
|
51 | regaining | 78
|
52 | resource-impact | 1
|
53 | rheumatics | 1
|
54 | scorpiops | 3
|
55 | spermograms | 2
|
56 | technology.though | 1
|
57 | tolerating | 86
|
58 | us/european | 1
|
Words in suffix order
1 | pre-9/11 | 2
|
2 | 2,351 | 3
|
3 | consciousness≥1 | 1
|
4 | non-p53 | 1
|
5 | 2002-4 | 1
|
6 | 16654 | 1
|
7 | 11,925 | 1
|
8 | 2003/2007 | 1
|
9 | disease/diagnostic | 1
|
10 | rca-d | 1
|
11 | btk-based | 1
|
12 | pegaptanib-associated | 1
|
13 | pathogen-stimulated | 1
|
14 | england-adopted | 1
|
15 | cardiology–suggested | 1
|
16 | guideline-derived | 1
|
17 | mice—and | 1
|
18 | rapid-turnaround | 1
|
19 | bupropion-hydrochloride | 1
|
20 | newcastle-lake | 1
|
21 | reaching | 2,118
|
22 | approaching | 360
|
23 | eating/feeling | 2
|
24 | regaining | 78
|
25 | celastrol-containing | 1
|
26 | attaining | 312
|
27 | apportioning | 2
|
28 | chuanping | 2
|
29 | declaring | 24
|
30 | losing | 314
|
31 | recreating | 5
|
32 | recalibrating | 3
|
33 | tolerating | 86
|
34 | re-reporting | 1
|
35 | 'setting | 3
|
36 | achieving | 4,385
|
37 | pyrimidine-rich | 1
|
38 | technology.though | 1
|
39 | fbih | 1
|
40 | lvdd-with | 1
|
41 | asai | 2
|
42 | nondeletional | 6
|
43 | perfectsil | 1
|
44 | 0.78mg/ml | 1
|
45 | us/european | 1
|
46 | ekbatan | 2
|
47 | 14.in | 1
|
48 | 1-s-duration | 1
|
49 | rheumatics | 1
|
50 | hyperaspidinols | 1
|
51 | spermograms | 2
|
52 | scorpiops | 3
|
53 | 61-years | 2
|
54 | chaerilus | 1
|
55 | resource-impact | 1
|
56 | common-law | 1
|
57 | ha-therapy | 2
|
58 | 1020-hz | 1
|